Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

Cancer

Volumn 121, Issue 22, 2015, Pages 4007-4015

  Buchbinder, Elizabeth I ^a   Sosman, Jeffrey A ^b   Lawrence, Donald P ^c   McDermott, David F ^d   Ramaiya, Nikhil H ^a   Van Den Abbeele, Annick D ^a,e   Linette, Gerald P ^f   Giobbie Hurder, Anita ^a   Hodi, F Stephen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f WASHINGTON UNIVERSITY   (United States)

Author keywords

acral melanoma; KIT; mucosal melanoma; sunitinib; vascular endothelial growth factor (VEGF)

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADVERSE OUTCOME; ARTICLE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; KIT GENE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MUCOSAL MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; NEUTROPENIA; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; CLINICAL TRIAL; GENETICS; MELANOMA; MORTALITY; MUCOSA; MUTATION; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MUCOUS MEMBRANE; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; SKIN NEOPLASMS;

EID: 84946500484     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29622     Document Type: Article

References (40)

1. Curtin JA, Fridlyand J, Kageshita T, et al., Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353: 2135-2147.
2. Batsakis JG, Suarez P,. Mucosal melanomas: a review. Adv Anat Pathol. 2000; 7: 167-180.
3. Tomicic J, Wanebo HJ,. Mucosal melanomas. Surg Clin North Am. 2003; 83: 237-252.
4. Curtin JA, Busam K, Pinkel D, Bastian BC,. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24: 4340-4346.
5. Rivera RS, Nagatsuka H, Gunduz M, et al., C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch. 2008; 452: 27-32.
6. Hodi FS, Corless CL, Giobbie-Hurder A, et al., Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013; 31: 3182-3190.
7. Hodi FS, Friedlander P, Corless CL, et al., Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008; 26: 2046-2051.
8. Carvajal RD, Antonescu CR, Wolchok JD, et al., KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305: 2327-2334.
9. Kluger HM, Dudek AZ, McCann C, et al., A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011; 117: 2202-2208.
10. Graells J, Vinyals A, Figueras A, et al., Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 2004; 123: 1151-1161.
11. Streit M, Detmar M,. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 2003; 22: 3172-3179.
12. Schuster C, Eikesdal HP, Puntervoll H, et al., Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One. 2012; 7: e38364.
13. Mahalingam D, Malik L, Beeram M, et al., Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2014; 74: 77-84.
14. Hodi FS, Lawrence D, Lezcano C, et al., Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014; 2: 632-642.
15. Imbulgoda A, Heng DY, Kollmannsberger C,. Sunitinib in the treatment of advanced solid tumors. Recent Results Cancer Res. 2014; 201: 165-184.
16. Motzer RJ, Hutson TE, Tomczak P, et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
17. Prior JO, Montemurro M, Orcurto MV, et al., Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009; 27: 439-445.
18. Heinrich MC, Corless CL, Demetri GD, et al., Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21: 4342-4349.
19. Chapman PB, Hauschild A, Robert C, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
20. Larkin J, Ascierto PA, Dreno B, et al., Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371: 1867-1876.
21. Robert C, Karaszewska B, Schachter J, et al., Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372: 30-39.
22. Ugurel S, Hildenbrand R, Zimpfer A, et al., Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005; 92: 1398-1405.
23. Wyman K, Atkins MB, Prieto V, et al., Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006; 106: 2005-2011.
24. Kim KB, Eton O, Davis DW, et al., Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008; 99: 734-740.
25. Guo J, Si L, Kong Y, et al., Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29: 2904-2909.
26. Woodman SE, Trent JC, Stemke-Hale K, et al., Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009; 8: 2079-2085.
27. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P,. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol. 2008; 5: 737-740.
28. Cho JH, Kim KM, Kwon M, Kim JH, Lee J,. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs. 2012; 30: 2008-2014.
29. Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC,. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res. 2012; 18: 1457-1463.
30. Varker KA, Biber JE, Kefauver C, et al., A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007; 14: 2367-2376.
31. Vihinen PP, Hernberg M, Vuoristo MS, et al., A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res. 2010; 20: 318-325.
32. Barrios CH, Hernandez-Barajas D, Brown MP, et al., Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer. 2012; 118: 1252-1259.
33. Lovly C, Pao W, Sosman J,. KIT c.1676T>A (V559D) mutation in melanoma. http://www.mycancergenome.org/content/disease/melanoma/kit/113/. Updated August 8, 2014. Accessed June 2015.
34. Terheyden P, Houben R, Pajouh P, Thorns C, Zillikens D, Becker JC,. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol. 2010; 130: 314-316.
35. Zhu Y, Si L, Kong Y, et al., Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma [abstract]. J Clin Oncol. 2009; 27 (suppl): e20017.
36. Carvajal RD, Lawrence DP, Weber J, et al., Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer Res. 2015; 21: 2289-2296.
37. Joosten SC, Hamming L, Soetekouw PM, et al., Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 2015; 1855: 1-16.
38. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
39. Topalian SL, Sznol M, McDermott DF, et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32: 1020-1030.
40. Robert C, Ribas A, Wolchok JD, et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384: 1109-1117.